Cluster of influenza a cases in vaccinated population of adults in virology laboratory in glasgow in december 2012

Scottish Medical Journal

Volumn 59, Issue 2, 2014, Pages 95-102

  Bradley Stewart, A ^a   Miller, R S ^a   Maclean, A ^a   Aitken, C ^a   Whittaker, L ^b   Gregory, V ^b   Daniels, R ^b   Gunson, R ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

H3N2; Influenza; Outbreak; Vaccine effectiveness

Indexed keywords

1 (SUBSTITUTED PHENYL) 3 [5 (2 SUBSTITUTEDPHENYL) 1 3 4 THIADIAZOL 2YL] UREA 1; 1 (SUBSTITUTED PHENYL) 3 [5 (2 SUBSTITUTEDPHENYL) 1 3 4 THIADIAZOL 2YL] UREA 2; 1 (SUBSTITUTED PHENYL) 3 [5 (2 SUBSTITUTEDPHENYL) 1 3 4 THIADIAZOL 2YL] UREA 3; 1, 3, 4 THIADIAZOLE DERIVATIVE; 5 (2 HYDROXYPHENYL) 2 AMINO [1 3 4] THIADIAZOLE; 5 (3 CHLOROPHENYL) 2 AMINO [1 3 4] THIADIAZOLE; 5 (4 NITROPHENYL) 2 AMINO [1 3 4] THIADIAZOLE; AMOXICILLIN; AMPHOTERICIN B; ASCORBIC ACID; HYDROGEN; NITRIC OXIDE; OFLOXACIN; UNCLASSIFIED DRUG; INFLUENZA VACCINE;

ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPERGILLUS NIGER; BACILLUS SUBTILIS; CANDIDA ALBICANS; DPPH RADICAL SCAVENGING ASSAY; ELECTRON; ESCHERICHIA COLI; GROWTH INHIBITION; INFRARED SPECTROMETRY; MASS SPECTROMETRY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; SPECTROPHOTOMETRY; STAPHYLOCOCCUS AUREUS; THIN LAYER CHROMATOGRAPHY; ADULT; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HOSPITAL LABORATORY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H3N2; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VACCINATION;

ADULT; DISEASE OUTBREAKS; FEMALE; HEALTH PERSONNEL; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LABORATORIES, HOSPITAL; MALE; SCOTLAND; SENTINEL SURVEILLANCE; VACCINATION;

EID: 84922480611     PISSN: 00369330     EISSN: 20456441     Source Type: Journal    
DOI: 10.1177/0036933014529057     Document Type: Article

References (17)

1. Health Protection Scotland (HPS). Monthly National Influenza Report–Summary of surveillance of influenza and other seasonal respiratory illnesses–Month ending 20 January 2013, week 03.
2. Health Protection Agency (HPA). National Influenza Report–Weekly National Influenza Graphs (published 7 February 2013).
3. WHO Influenza Centre (NIMR) London. Interim Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2013/14. February 2013; pp.1–85.
4. McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/ 13. Eurosurveillance 2013; 18: 31.
5. Health Protection Scotland (HPS). Monthly National Influenza Report–Summary of surveillance of influenza and other seasonal respiratory illnesses–Month ending 23 December 2012, week 51.
6. Gunson RN, Collins TC and Carman WF. Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reactions. J Clin Virol 2005; 33: 341–344.
7. Gunson RN, MacLean A, Davies E, et al. Development of a multiplex real-time RT-PCR that allows universal detection of inFuenza A viruses and simultaneous typing of inFuenzaA/H1N1/2009 virus. J Virol Meth 2010; 163: 258–261.
8. Lin YP, Gregory V, Collins P, et al. Neuraminidase receptor binding variants of human influenza A (H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 2010; 84: 6769–6781.
9. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Geneva: WHO, 23 February 2012.
10. Bragstad K, Emborg HD, Fischer TK, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13–a rapid epidemiological and virological assessment. Eurosurveillance 2013; 18: 20397.
11. Zangwill KM and Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004; 23: 189–197.
12. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 36–44. Review. Erratum in: Lancet Infect Dis 2012; 12: 655.
13. Skowronski DM, Janjua NZ, De Serres G, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013. Eurosurveillance 2013; 18: 1–10.
14. CDC. CDC Report on Influenza vaccine efficacy. Early Estimates of Seasonal Influenza Vaccine Effectiveness–United States, January 2013. Morbid Mortal Wkly Rep (MMWR) 2013; 62: 32–35.
15. Wiley DC, Wilson IA and Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289: 373–378.
16. Ryan-Poirier K and Kawaoka Y. Distinct glycoprotein inhibitors of Influenza A virus in different animal sera. J Virol 1991; 65: 389–395.
17. Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the a-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77: 8418–8425.